Related Experiment Videos
Halothane reduces dysrhythmias and improves contractile function after global hypoperfusion in isolated hearts
N Buljubasic1, J Marijic, D F Stowe
1Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226.
Anesthesia and Analgesia
|March 1, 1992
Summary
Halothane demonstrated cardiac protective effects during hypoperfusion and reperfusion in guinea pig hearts, reducing ventricular fibrillation. However, it also increased supraventricular tachycardia incidence in some cases.
Area of Science:
- Cardiology
- Anesthesiology
- Physiology
Background:
- Hypoperfusion can lead to cardiac dysfunction and arrhythmias.
- Anesthetic agents like halothane may influence cardiac responses during ischemia and reperfusion.
- Understanding these effects is crucial for patient safety during surgical procedures.
Purpose of the Study:
- To investigate the effects of halothane on cardiac function during graded hypoperfusion and subsequent reperfusion in an isolated perfused guinea pig heart model.
- To assess halothane's impact on heart rate, atrioventricular conduction, dysrhythmias, and left ventricular pressure.
- To determine if halothane provides cardiac protection against hypoperfusion-induced injury.
Main Methods:
- Isolated perfused guinea pig hearts (n=85) were subjected to 30 minutes of hypoperfusion at 0%, 10%, or 25% of control perfusion pressure.
- Hearts were exposed to 0%, 0.74%, or 1.65% halothane before, during, and after hypoperfusion.
- Cardiac function parameters including heart rate, AV conduction time, and left ventricular systolic pressure (LVSP) were measured.
- Incidence and duration of dysrhythmias during reperfusion were recorded.
Main Results:
- Halothane exposure decreased heart rate and LVSP, and increased AV conduction time prior to hypoperfusion.
- During reperfusion, halothane significantly reduced the duration of ventricular fibrillation in the 0% and 10% hypoperfusion groups.
- Halothane increased the incidence of supraventricular tachycardia in some groups, but 1.65% halothane facilitated LVSP recovery in the 25% hypoperfusion group.
Conclusions:
- Halothane exhibits protective cardiac effects, reducing ventricular fibrillation severity after graded hypoperfusion.
- These protective effects may stem from reduced cardiac workload or direct cellular mechanisms.
- However, halothane can also increase the risk of supraventricular tachycardia, necessitating careful consideration of its use.